EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Development of bispecific T cell engagers: harnessing quantitative systems pharmacology

Timothy Qi, Xiaozhi Liao, Yanguang Cao

Trends in Pharmacological Sciences · 2023-12 · 44 (12) · 880-890

DOI: 10.1016/j.tips.2023.09.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2023-12. Verfasst von Timothy Qi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill,…. Hauptthemen laut MEDLINE: Pharmacology, Antibodies, Bispecific. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific T cell engagers (bsTCEs) have emerged as a promising class of cancer immunotherapy. Several bsTCEs have achieved marketing approval; dozens more are under clinical investigation. However, the clinical development of bsTCEs remains rife with challenges, including nuanced pharmacology, limited translatability of preclinical findings, frequent on-target toxicity, and convoluted dosing regimens. In this opinion article we present a distinct perspective on how quantitative systems pharmacology (QSP) can serve as a powerful tool for overcoming these obstacles. Recent advances in QSP modeling have empowered developers of bsTCEs to gain a deeper understanding of their context-dependent pharmacology, bridge gaps in experimental data, guide first-in-human (FIH) dose selection, design dosing regimens with expanded therapeutic windows, and improve long-term treatment outcomes. We use recent case studies to exemplify the potential of QSP techniques to support future bsTCE development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacologyAntibodies, BispecificHumansT-LymphocytesNetwork PharmacologyImmunotherapy

Stichwörter der Autor:innen

bispecific T cell engagercancerquantitative systems pharmacology

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, The University…

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences
  • National Institutes of Health

Zitieren

APA

Qi, T., Liao, X., & Cao, Y. (2023). Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends in Pharmacological Sciences, 44(12), 880-890. https://doi.org/10.1016/j.tips.2023.09.009

Vancouver

Qi T, Liao X, Cao Y. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends in Pharmacological Sciences. 2023;44(12):880-890. doi:10.1016/j.tips.2023.09.009

BibTeX
@article{Qi2023,
  author = {Qi, Timothy and Liao, Xiaozhi and Cao, Yanguang},
  title = {Development of bispecific T cell engagers: harnessing quantitative systems pharmacology},
  journal = {Trends in Pharmacological Sciences},
  year = {2023},
  volume = {44},
  number = {12},
  pages = {880--890},
  doi = {10.1016/j.tips.2023.09.009}
}
Kostenlos starten →